Wednesday, December 17, 2025 The CEC1 (EORTC 26053-22054) Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial has permanently closed. The letter of permanent trial closure can be found in the members' area of the CCTG webpage under "Toolbox-Reports-Trial Closure" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closureRATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma.PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.Primary PublicationLoree JM, Titmuss E, O'Callaghan CJ, Brown CJ, Madison R, Jonker DJ, Aleshin A, Gordon V, Patel S, Caycedo-Marulanda A, Young A, Huang Y, Camara W, Fine A, Pokharel P, Tu D, Kennecke HF. Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay. JCO Oncology Advances 2: e2500055. 2025.https://ascopubs.org/doi/abs/10.1200/OA-25-00055 Clinicaltrials.gov Results Reporting: https://www.clinicaltrials.gov/study/NCT00626990
